Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma

Satoshi Narahara, Takehisa Watanabe, Katsuya Nagaoka, Nahoko Fujimoto, Yoki Furuta, Kentaro Tanaka, Takayuki Tokunaga, Takeshi Kawasaki, Yoko Yoshimaru, Hiroko Setoyama, Kentaro Oniki, Junji Saruwatari, Masakuni Tateyama, Hideaki Naoe, Motohiko Tanaka, Yasuhito Tanaka, Yutaka Sasaki – 26 November 2021 – Advanced hepatocellular carcinoma (HCC) remains a highly lethal malignancy, although several systemic therapeutic options are available, including sorafenib (SFN), which has been one of the standard treatment agents for almost a decade.

North American Biliary Stricture Management Strategies in Children After Liver Transplantation: A Multicenter Analysis From the Society of Pediatric Liver Transplantation (SPLIT) Registry

Pamela L. Valentino, Tianhao Wang, Veronika Shabanova, Vicky Lee Ng, John C. Bucuvalas, Amy G. Feldman, Regino P. Gonzalez‐Peralta, Nitika Arora Gupta, Tamir A. Miloh, Saeed Mohammad, Erika Pace, Shikha S. Sundaram, Nada A. Yazigi, Kyle Soltys, Society of Pediatric Liver Transplantation (SPLIT) – 26 November 2021 – Biliary strictures affect 4%‐12% of pediatric liver transplantations. Biliary strictures can contribute to graft loss if left untreated; however, there remains no consensus on the best course of treatment.

High‐Resolution Exposomics and Metabolomics Reveals Specific Associations in Cholestatic Liver Diseases

Douglas I. Walker, Brian D. Juran, Angela C. Cheung, Erik M. Schlicht, Yongliang Liang, Megan Niedzwiecki, Nicholas F. LaRusso, Gregory J. Gores, Dean P. Jones, Gary W. Miller, Konstantinos N. Lazaridis – 25 November 2021 – Progress in development of prognostic and therapeutic options for the rare cholestatic liver diseases, primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), is hampered by limited knowledge of their pathogeneses.

Subscribe to